GIM
CRL icon

Glenmede Investment Management’s Charles River Laboratories CRL Stock Holding History

Glenmede Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$408K Sell
2,606
-389
-13% -$61.8K ﹤0.01% 1008
2025
Q2 		$454K Buy
+2,995
New +$399K ﹤0.01% 956

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Glenmede Investment Management's CRL Position: Q3 2025 in Review

Glenmede Investment Management reduced its Charles River Laboratories (CRL) stake by 13% in Q3 2025, selling an estimated $61.8K and leaving 2,606 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

Glenmede Investment Management first reported a position in CRL in Q2 2025 and has held it in 2 quarters since. The position peaked at $454K in Q2 2025. 555 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Glenmede Investment Management held 2,606 shares of Charles River Laboratories worth $408K as of Q3 2025.
  • Glenmede Investment Management sold 389 Charles River Laboratories shares in Q3 2025, an estimated $61.8K.
  • Charles River Laboratories made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1008 holding.
  • Glenmede Investment Management first reported a position in Charles River Laboratories in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Charles River Laboratories position peaked at $454K in Q2 2025.
  • 555 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.